Itolizumab

Research use only, not for human use.

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production.

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

Itolizumab (100 μg/mL) inhibits T cell proliferation.Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs.Itolizumab (40 μg/mL) reduces CD26hiCD161+?CD8+?T cells during culture of PBMCs overnight.Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions.

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD).Animal Model:Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)Dosage:60 μg or 300μg Administration:Intraperitoneal injection (i.p.), prior to PBMC transplantation. Result:Decreased mortality compared to the vehicle (100% vs. 10%).

——

Others

Other Targets

Others

——

——

1116433-11-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years